H.C. Wainwright analyst Oren Livnat raised the firm’s price target on Pacira BioSciences to $71 from $69 and keeps a Buy rating on the shares post the Q4 results. The analyst says the company’s sales guidance was conservative due to pandemic and inflation-related macro headwinds. A "very long" Exparel growth runway, Zilretta, and upside optionality or Iovera and the early-stage pipeline make Pacira a "potential very attractive strategic acquisition target," the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PCRX:
- Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results
- Pacira sees 2023 EXPAREL net sales $570M-$580M
- Pacira reports Q4 adjusted EPS 80c, consensus 83c
- Pacira, LPGA partner to raise awareness of non-opioid pain management solutions
- Pacira to Report 2022 Financial Results on Tuesday February 28, 2023